CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1101/2023.04.13.536740

License

CC-BY

Other Formats

PDF